Entrada Therapeutics(TRDA)

Focus: Entrada Therapeutics is a public biotech company specializing in delivering biologics to the cytosol, targeting rare diseases across neurology, ophthalmology, and gastroenterology. The company operates as a clinical-stage developer with a proprietary delivery platform.

Rare Diseases Neurology Ophthalmology Gastroenterology

Profile data last refreshed 4h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

7+1 this month

Stable — net +1 jobs in 30d

3 added, 2 removed. Backfill posture.

Should You Work at Entrada Therapeutics?

AI assessment

Best suited for scientists and operators who thrive in small, early-stage biotech environments with long timelines and want exposure to innovative delivery science; higher execution risk than late-stage companies.

Why Work Here

Public company with positive FY2025 net income ($66M) and 63% revenue growth YoY ($211M), demonstrating operational momentum and financial stability.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$211M

Pipeline & Clinical Trials

Non-interventional

Mitochondrial Neurogastrointestinal Encephalomyopathy

N/A

Clinical Trials (1)

NCT04245917Natural History Study of MNGIE

N/A

Help build intelligence for Entrada Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

High R&D intensity (59%) and focused pipeline in rare genetic diseases (DMD, mitochondrial disorders) indicate deep scientific commitment with fewer commercial pressures.

Small but stable hiring footprint (7 active roles) across clinical, supply chain, and regulatory functions suggests selective, quality-driven team building.

Watch Out For

No marketed products and only Phase 1/2 programs with zero Phase 3 trials means 5+ years to potential FDA approval; career progression tied entirely to pipeline success.
Recent insider selling activity (September 2026) by MPM Capital Partners without 10b5-1 plans signals potential leadership confidence concerns during a growth phase.
Limited public hiring (7 roles) and unknown headcount make it difficult to assess organizational growth trajectory or internal advancement opportunities.

Generated by Claude from Entrada Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

ENTR-601-44

Duchenne Muscular Dystrophy (DMD)

PHASE_1_2

Clinical Trials (2)

NCT07682129Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Evaluate the Safety and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)

Phase 2

NCT07037862A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping to Evaluate the Safety and Efficacy of ENTR-601-44

Phase 1/2

ENTR-601-45

Duchenne Muscular Dystrophy (DMD)

PHASE_1_2

Clinical Trials (1)

NCT07038824A Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping to Evaluate the Safety and Efficacy of ENTR-601-45

Phase 1/2

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Rare Diseases, Gastroenterology

Publications: 5 in PubMed

SEC Filings: 2 available

Open Roles: 7 active jobs

Therapeutic Area Focus

Rare Diseases

3 pipeline

Gastroenterology

1 pipeline

Marketed

Pipeline

Financials (FY2025)

Revenue

$211M63%

R&D Spend

$125M(59%)25%

Net Income

$66M

Hiring Trend

Stable

Open Roles

Added

-1

Filled/Removed

Based on last 4 crawl cycles

Research Publications(5)

Recent peer-reviewed publications with author affiliations at this company

Enhanced antisense oligonucleotide delivery reveals that transcript turnover impacts apparent splicing rescue in myotonic dystrophy.

Molecular therapy : the journal of the American Society of Gene Therapy

2026

PMID:42163456

Targeting the Expanded TCF4/Fuchs' Endothelial Corneal Dystrophy CUG Repeat with Morpholino Peptide Conjugates.

ACS omega

2023

PMID:38024683

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Entrada Therapeutics(TRDA)

Should You Work at Entrada Therapeutics?

Why Work Here

Pipeline & Clinical Trials

Watch Out For

Recent News · Entrada Therapeutics(10)

Open Jobs (7)

Clinical Pharmacology Consultant

Manager, Commercial Strategy Analytics

Clinical Scientist (CONSULTANT)

SEC Reporting & Technical Accounting Consultant

Associate Director, Drug Product Development & Manufacturing

Associate Director, Analytical Development & Quality Control

Director, Regulatory Writing

Financials (FY2025)

Hiring Trend

Research Publications(5)